Several agreements Hyperfine Inc. has negotiated with distributors will enable the company to provide its brain imaging system (Swoop) to Turkey, Israel, and Saudi Arabia. These latest contracts strengthen Hyperfine’s global expansion strategy, broadening access to magnetic resonance (MR) brain imaging in regions with large populations, low penetration of MRI, and significant unmet healthcare needs.

“We have achieved several milestones throughout 2024 that have positioned us for significant growth in international markets in 2025,” Hyperfine Chief Commercial Officer David Castiglioni said. “Agreements with these new partners build on our existing distribution networks, giving Hyperfine global reach. The interest from international clinicians and healthcare facilities reflects the growing global enthusiasm for portable MR brain imaging and its potential to bridge critical healthcare gaps.”

The new distribution agreements in Turkey, Israel, and Saudi Arabia add to agreements established earlier in 2024 targeting future expansion across 13 European markets, India, Malaysia, and Indonesia—broadening the reach of Hyperfine to encompass North America, Europe, Asia, Oceania, and the Middle East. In October 2024, Hyperfine was granted CE approval in Europe for its latest ninth-generation AI-powered software. This most recent software approval, combined with the extensive distribution network, positions Hyperfine for significant growth in 2025 and beyond.

The new distribution partnerships ensure efficient market entry and afford Hyperfine strong local support for adopting the Swoop system. These areas, home to more than 100 million people, face challenges in providing timely neurological care, particularly in remote and emergency settings lacking access to advanced imaging equipment. With its portability and cost-effectiveness, the Swoop system eliminates barriers posed by conventional MRI systems, enabling clinicians to deliver high-quality imaging at the point of care.

“We feel the Swoop system can play a very valuable role in advancing neurological care globally,” Castiglioni added. “International markets have significantly lower penetration of conventional MRI, and a portable and affordable MR brain imaging option is a valuable solution to serve large areas of unmet need in those markets.”

The Swoop Portable MR Imaging system is cleared by the U.S. Food and Drug Administration (FDA) for brain imaging. It is a portable, ultra-low-field magnetic resonance imaging device for producing images that display the head’s internal structure where full diagnostic examination is not clinically practical. When interpreted by a trained physician, these images provide information that can be useful in determining a diagnosis. The Swoop system also has CE certification in the European Union and UKCA certification in the United Kingdom. The Swoop system is commercially available in a select number of international markets.

Hyperfine Inc. is striving to redefine brain imaging with the Swoop system—the first FDA-cleared, portable, ultra-low-field, magnetic resonance brain imaging system that provides imaging at multiple points of professional care. Founded by Dr. Jonathan Rothberg in a technology-based incubator called 4Catalyzer, Hyperfine scientists, engineers, and physicists developed the Swoop system to improve brain imaging methodology and the ways clinicians can apply accessible diagnostic imaging to patient care.